A Randomized Controlled Trial Evaluating Outcome Impact of Cilostazol in Patients with Coronary Artery Disease or at a High Risk of Cardiovascular Disease.

J Pers Med · 2022 · PMC9225272 · PMID 35743723

Europe PMC DOI

hedged sentence

0.2500

closest p · 5.0× alpha

0.2500

boldest claim

The sentences

borderline significantp = 0.25not close (p > 0.1)

By intention-to-treat analysis, the composite endpoints of MACE occurred in 14 patients in the cilostazol group (10.4%) and in 20 patients in the placebo group (15.2%), leading to a borderline significant risk reduction in the primary composite endpoints (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.34–1.33, p = 0.25) with cilostazol treatment.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.